DT-109
Induces glutathione biosynthesis / Glycine-containing peptide which has been demonstrated to ameliorate nonalcoholic fatty liver disease (NAFLD). It improved body composition, and lowered circulating glucose, lipids, transaminases, proinflammatory cytokines and steatohepatitis in mice with established NASH.1 It dose-dependently attenuates NASH and fibrosis in mice as well as in nonhuman primates.2 It induced glutathione biosynthesis in mononuclear cells and demonstrated atheroprotective activity.3
Biochemicals & reagents
14857-82-0
Gly-Gly-Leu-OH
1 Rom et al. (2020), Glycine-based treatment ameliorates NAFLD by modulating fatty acid oxidation, glutathione synthesis, and the gut microbiome; Sci. Transl. Med., 12 eaaz2841 2 Qu et al. (2023), DT-109 ameliorates nonalcoholic steatohepatitis in nonhuman primates; Cell Metab., 35 742 3 Rom et al. (2022), Induction of glutathione biosynthesis by glycine-based treatment mitigates atheroscleosis; Redox. Biol., 52 102313
-20°C
TARGET: Glutathione -- PATHWAY: Glucose metabolism; Cytokine; Fatty acid metabolism -- DISEASE AREA: Liver disease; Atherosclerosis